SAGE Therapeutics Inc Forecasted to Post FY2019 Earnings of ($13.76) Per Share (NASDAQ:SAGE)

SAGE Therapeutics Inc (NASDAQ:SAGE) – Oppenheimer lowered their FY2019 EPS estimates for SAGE Therapeutics in a research report issued on Tuesday, November 12th. Oppenheimer analyst J. Olson now anticipates that the biopharmaceutical company will earn ($13.76) per share for the year, down from their previous forecast of ($13.37). Oppenheimer currently has a “Outperform” rating and a $190.00 target price on the stock. Oppenheimer also issued estimates for SAGE Therapeutics’ Q4 2019 earnings at ($3.62) EPS, FY2020 earnings at ($8.34) EPS, FY2021 earnings at ($5.08) EPS, FY2022 earnings at $2.72 EPS and FY2023 earnings at $7.46 EPS.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.41) by ($0.07). SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The company had revenue of $3.57 million during the quarter, compared to analyst estimates of $2.52 million. During the same period last year, the business earned ($2.63) earnings per share. The firm’s revenue was up 35600.0% compared to the same quarter last year.

SAGE has been the subject of a number of other reports. JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. Canaccord Genuity lowered their target price on SAGE Therapeutics from $220.00 to $218.00 and set a “buy” rating for the company in a report on Wednesday. William Blair restated a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. BidaskClub cut SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, November 1st. Finally, ValuEngine cut SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the stock. SAGE Therapeutics has a consensus rating of “Buy” and a consensus price target of $201.00.

Shares of SAGE opened at $146.32 on Friday. The stock has a fifty day simple moving average of $141.78 and a two-hundred day simple moving average of $163.50. SAGE Therapeutics has a 52-week low of $79.88 and a 52-week high of $193.56. The company has a market capitalization of $7.46 billion, a PE ratio of -18.11 and a beta of 2.49. The company has a quick ratio of 16.00, a current ratio of 12.67 and a debt-to-equity ratio of 0.03.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of SAGE Therapeutics by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 4,606,430 shares of the biopharmaceutical company’s stock valued at $843,392,000 after buying an additional 40,731 shares during the period. Jennison Associates LLC boosted its stake in shares of SAGE Therapeutics by 25.4% in the 2nd quarter. Jennison Associates LLC now owns 2,953,913 shares of the biopharmaceutical company’s stock valued at $540,832,000 after buying an additional 598,299 shares during the period. BlackRock Inc. boosted its stake in shares of SAGE Therapeutics by 2.8% in the 2nd quarter. BlackRock Inc. now owns 2,748,713 shares of the biopharmaceutical company’s stock valued at $503,261,000 after buying an additional 75,246 shares during the period. Invesco Ltd. boosted its stake in shares of SAGE Therapeutics by 197.2% in the 2nd quarter. Invesco Ltd. now owns 2,021,964 shares of the biopharmaceutical company’s stock valued at $370,201,000 after buying an additional 1,341,720 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of SAGE Therapeutics by 12.3% in the 2nd quarter. Janus Henderson Group PLC now owns 1,873,408 shares of the biopharmaceutical company’s stock valued at $343,002,000 after buying an additional 204,779 shares during the period.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: How Do Mutual Funds Work?

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.